FY2024 EPS Estimates for YS Biopharma Co., Ltd. Lowered by Analyst (NASDAQ:YS)

YS Biopharma Co., Ltd. (NASDAQ:YS) – Research analysts at Diamond Equity lowered their FY2024 earnings per share (EPS) estimates for YS Biopharma in a research report issued to clients and investors on Monday, April 22nd. Diamond Equity analyst H. Diamond now anticipates that the company will earn ($0.45) per share for the year, down from their prior forecast of ($0.24). The consensus estimate for YS Biopharma’s current full-year earnings is ($0.45) per share. Diamond Equity also issued estimates for YS Biopharma’s Q4 2024 earnings at ($0.08) EPS, Q1 2025 earnings at ($0.09) EPS, Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.02) EPS and FY2025 earnings at ($0.25) EPS.

YS Biopharma Stock Performance

NASDAQ:YS opened at $0.80 on Thursday. YS Biopharma has a one year low of $0.35 and a one year high of $1.97. The company has a quick ratio of 1.09, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The stock has a 50 day moving average price of $0.67 and a 200 day moving average price of $0.58.

Institutional Investors Weigh In On YS Biopharma

A hedge fund recently bought a new stake in YS Biopharma stock. Superstring Capital Management LP purchased a new position in shares of YS Biopharma Co., Ltd. (NASDAQ:YS) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 307,920 shares of the company’s stock, valued at approximately $166,000. Superstring Capital Management LP owned 0.33% of YS Biopharma as of its most recent SEC filing. Institutional investors own 52.64% of the company’s stock.

YS Biopharma Company Profile

YS Biopharma Co, Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001.